Q-omics provides the consensus-scored SNHG14 profile across patient tissues and cancer cell-line models. SNHG14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNHG14 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, SNHG14 RNA expression shows 20,732 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BLCA, and THYM as cancer lineages where SNHG14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG14 survival associations across molecular data types. SNHG14 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG14 RNA expression–survival associations across cancer types. High SNHG14 expression shows unfavorable associations in UVM and ACC, but favorable associations in PAAD, UCS, HNSC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNHG14 RNA expression.
This table summarizes SNHG14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG14 shows lower tumor expression in BLCA, THCA, KIRC, BRCA, KIRP and LUSC. The BLCA box plot shows higher SNHG14 RNA expression in normal versus tumor tissue (log2 FC = −2.014, t-test p < 0.001).
This table shows molecular features associated with SNHG14 in patient tissues and cancer cell lines. In patient samples, SNHG14 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
